This FTSE small cap is up over 800% in 2020. Here’s what I’d do now

This Fool looks at a FTSE AIM small-cap company whose share price has increased massively as it works on a coronavirus treatment.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE and global markets have crashed in the past three months. This is a result of the coronavirus pandemic and related economic shutdown. 

Biotech and healthcare companies are now in a race to try to create a vaccine. As well as a vaccine, some companies are creating other tools in response to the virus such as apps for testing information.

It’s not just the major pharmaceutical companies that are working hard to create a vaccine. There are other smaller companies you may not have heard of who are also in the fight. One such company is Synairgen (LSE:SNG). 

FTSE AIM resident

Synairgen is a respiratory drug discovery and development company founded by three University of Southampton professors. Its primary focus is on lung viral defence and its current product, known as SNG001, may have potential coronavirus applications.

Synairgen has been on the FTSE AIM index for nearly 15 years so it is not a company created in direct response to the pandemic. It has access to the scientific and clinical research facilities of Southampton General Hospital. 

SNG001 is wholly owned by Synairgen and is based on existing intravenous antiviral treatment. A potential new inhaler version could deliver it straight to the lungs. This is where damage is done by the coronavirus. Synairgen could benefit from having a tried and tested drug, in comparison to other companies that are starting from scratch. 

Recent news and performance

At the end of March, Synairgen announced its plans for testing SNG001. Its CEO commented, “A successful outcome from this trial in Covid-19 patients would be a major breakthrough in the fight against this coronavirus pandemic.” 

Since the turn of the year, Synairgen’s share price has increased over 800%. This makes it one of the best performing stocks in the UK in 2020. It is easy to understand why its share price has risen rapidly with the treatment it could potentially create. On 2 January, its per share price was 5.87p. At the time of writing it is closer to 55p. 

The company has been profitable in recent years although most of the money it makes is channelled back into research and development. This has resulted in some years showing a loss. After the trial announcement, Synairgen announced £14m in new funding based on offering new ordinary shares. It has confirmed this money would be used to fund the trials announced a week earlier. 

Verdict

I would not put all my eggs into one basket when it comes to coronavirus vaccine stocks. I would especially not put them all into a small cap company. However, I feel Synairgen is the type of low-price small cap that could be worth a gamble. I don’t see an issue in investing a small amount of money.

I would not be able to tell you how many companies there are out there trying to create vaccines and treatments. But I do know for certain that not all will succeed. So, as long as you understand that there are risks and you’re prepared for a loss, what is the harm in trying a small cap? Of course, you could play it safer and look to a bigger FTSE name such as GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Recently released: October’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Investing Articles

Here’s how a Stocks and Shares ISA and Lifetime ISA could supercharge my wealth!

Individual Savings Accounts (ISAs) can help UK share investors take their earnings to the next level. And their importance is…

Read more »

A person holding onto a fan of twenty pound notes
Investing Articles

A high-yield dividend ETF and an investment trust to consider this November!

Investors wanting to boost their passive income could benefit from investigating these high-yield funds and trusts, says Royston Wild.

Read more »

Investing Articles

2 of my favourite, cheap FTSE 100 growth shares this November!

These FTSE 100 growth shares could be great long-term picks to consider, reckons Royston Wild. At current prices he thinks…

Read more »

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

My favourite FTSE 100 passive income stock that keeps the Christmas coffers full

The holiday season is expensive and can leave many consumers struggling to make ends meet. Here’s how I use a…

Read more »

Investing Articles

The latest growth forecasts suggest the Glencore share price will hit 555p!

Harvey Jones has been disappointed by the performance of the Glencore share price since he bought the commodity stock last…

Read more »